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Native and recombinant neutrophil collagenase (MMP-8) was
shown to cleave at the E373-A374 'aggrecanase' site in the
interglobular domain of aggrecan. The time course of digestion
in vitro showed that MMP-8 cleaved initially at N341-F342, the
predominant metalloproteinase site, before cleaving at the
E373-A374 site. A synthetic peptide, IPENFFG, inhibited cleavage
at E373-A374 but not N341-F342 in vitro, indicating that the
INTRODUCTION
Aggrecan is the major proteoglycan in cartilage and is responsible
for its resilience and load-bearing properties. The loss ofaggrecan
is a major feature of cartilage degeneration associated with
arthritis. Normal turnover and pathological loss of aggrecan
from cartilage involves proteolytic cleavage of the core protein
and the most susceptible region is located at the N-terminus
where two globular domains, G1 and G2, are separated by a
short interglobular domain (IGD) (Figure 1). The IGF has been
identified as a key site of proteolytic attack, however the
proteinase(s) responsible for cleavage in the tissue have not been
identified.
The matrix metalloproteinases (MMPs) are thought to be
involved in aggrecan degradation, however there is controversy
as to which of the MMPs (1,2,3,8 or 9) are primarily responsible,
or whether several MMPs work in combination. In studies in
vitro using a purified G1-G2 substrate prepared from cartilage
aggrecan [1] we have identified cleavage sites specific for MMP-
1 (interstitial collagenase; EC 3.4.24.7), MMP-2 (gelatinase A;
EC 3.4.24.24), MMP-3 (stromelysin 1 EC 3.4.24.17), MMP-7
(matrilysin; EC 3.4.24.23), MMP-9 (gelatinase B; EC 3.4.24.35)
and MMP-8 (neutrophil collagenase; EC 3.4.24.34) [2-4]. The
results show that these MMPs cleave between N341 and F342
(based on the human aggrecan sequence [5]), and that this is the
preferred and predominant site of cleavage for this class of
enzyme. A minor MMP cleavage-site between D441 and L442 is
also present, however the incidence of cleavage at this site is low,
and not all the MMPs show this activity [3,4].
Other laboratories have identified a major cleavage-site within
aggrecan IGD that is different to the size identified for the MMPs
[6-10]. These studies have shown that under conditions ofnormal
and interleukin-l (IL-1)-stimulated turnover, bovine cartilage
E373-A374 sequence was a less preferred site for MMP-8 cleavage
than N341-F342. IPENFFG also inhibited release of A374 RGSVI
fragments from cartilage in explant culture, suggesting that a
metalloproteinase cleaved at the aggrecanase site in situ.
The possibility remains that 'aggrecanase' may be a metallo-
proteinase in cartilage.
explants release aggrecan fragments with N-terminal sequences
corresponding to cleavage between E373 and A374 [6-8]. In
addition, the major aggrecan fragments found in synovial fluids
from osteoarthritis and joint-injury patients result from cleavage
at the same E373-A374 bond [9,10]. The enzyme responsible for
this cleavage has been named aggrecanase but its identity remains
unknown. Sites in the IGD that are cleaved by cathepsin B [3],
leukocyte elastase [11], plasmin and urokinase [12] have also
been described, but do not correlate with aggrecanase cleavage.
In this paper we report that native and recombinant human
MMP-8 cleaves a G1-G2 substrate at the aggrecanase site. This
important finding establishes that an MMP is able to cleave at
the aggrecanase site whereas previous results suggested that this
class of enzyme was not responsible. Our results further show
that cleavage in vitro at the aggrecanase site occurs after cleavage
at the adjacent MMP site.
EXPERIMENTAL
Cystatin, E-64 and pepstatin were from Boehringer Mannheim,
Germany. Keratanase (Pseudomonas sp.) (EC 3.2.1.103) was
from Seikagaku Kogyo, Japan. Chondroitin ABC lyase (Proteus
vulgaris) (EC 4.2.2.4) and keratanase II (Bacillus sp.) were from
Seikagaku, U.S.A. Agarose type HSC was from PS Park Scientific
(Northampton, U.K.). Methods for the preparation of the
Gl-G2 substrate and polyclonal rabbit anti-G2 antiserum have
been described [1]. The purification of native MMP-8 from
human neutrophils [13], recombinant MMP-8 catalytic domain
fragment (14], rabbit-bone prostomelysin [15], recombinant hu-
man prostromelysin [16,17], recombinant human fibroblast pro-
collagenase [18], human progelatinase A [19] and recombinant
tissue inhibitor of metalloproteinase-1 (TIMP-1) [20] was as
described.
Abbreviations used: IGD, interglobular domain; MMPs, matrix metalloproteinases; PMSF, polymethanesulphonyr fluoride; SBTI, soybean trypsin
inhibitor; PEG, polyethylene glycol; IL-1, interleukin-1; TIMP-1, tissue inhibitor of metalloproteinase-1.
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Figure 1 Schematic representation of cleavage sites in the aggrecan
interglobular domain
The Gl, G2 and interglobular domains (b) are shown in relation to the complete aggrecan core-
protein (a). The cleaved fragments generated by the action of MMPs (c,e) and aggrecanase
(d,e) are shown. The only Gl product found was 50 kDa. The 60 kDa fragment predicted for
a primary cleavage at the aggrecanase site (d) was not detected. Cleavage at D441-L442 (e)
occurred at low incidence (20% or less). Small IGD fragments lacking globular domains (e)
F342-E373 {predicted relative molecular mass 5000-10000 Da) and A374-D441 (8000-15000)
were not detected. The size of the fragments is shown as their apparent relative molecular mass
on 5% SDS gels after keratanase digestion.
Enzyme digestions
MMP digestions were carried out in buffer containing 10 mM
calcium chloride, 100 mM sodium chloride and 50 mM Tris/HCl,
pH 7.5, at 37 °C, for the times specified. The digests contained
1 mM phenylmethanesulphonyl fluoride (PMSF), 2,M pep-
statin and either 40 ,ug/ml cystatin or 20 ,ug/ml E-64 as proteinase
inhibitors. Keratanase digestions were done in 50 mM-Tris/
acetate buffer, pH 7.5, at 37 °C overnight with 0.025 units of
keratanase per 30 jl, in the presence of 1OmM EDTA/100
,ug/ml cystatin/l mM PMSF. All MMP digested G1-G2 samples
were keratanase-treated prior to SDS/PAGE unless otherwise
stated. Keratanase-treated G2 digestion products were sequenced
directly from Immobilon membranes following SDS/PAGE and
electrotransfer. Immunodetection with the BC-3 monoclonal
antibody (1:1000) was as described [21].
Activation of pro-MMPs
The procollagenases (10 jug) were activated with 1 mM HgCl2 for
1 h at 37 °C, or alternatively, by incubation with 0.1 ,ug of
recombinant human prostromelysin and 0.5 jug of trypsin for 30
min at 37 °C in a total volume of 50 jul. Trypsin was inactivated
with 5 ,tg of soybean trypsin inhibitor (SBTI). Control-tubes
containing prostromelysin, trypsin and SBTI did not degrade the
G1-G2 substrate. Prostromelysin (0.25,g) was activated by
incubation with 70 mg of plasmin for 1 h at 37 °C, or 0.25 ,ug of
trypsin for 20 min at room temperature, followed by inhibition
with a 10-fold molar excess of aprotinin or SBTI respectively.
Explant cultures
Cartilage taken from the metacarpophalangeal joints of young
pigs was maintained in explant culture in Dulbecco's modified
Eagle's medium with supplements as described [22]. The explants
were equilibrated for 3 d in serum-free medium, then incubated
in medium containing human recombinant IL-za (10 mg/ml) for
24 h in the presence or absence of peptide (4 mg/ml). Control
cultures were maintained in serum-free medium with or without
peptide. After 24 h the medium was removed, dialysed against
distilled water and the concentration of sulphated glycosamino-
glycan determined using the 1,9-Dimethylmethylene Blue assay
[23]. Aliquots containing 5 ,ug of glycosaminoglycan were freeze-
dried and reconstituted in 8 M urea prior to electrophoresis on
composite gels [24]. Duplicate gels were either stained with
Toluidine Blue (0.27 %, w/v in acetic acid) or electrophoretically
transferred onto Hybond N+ membrane (Amersham). Before
immunodetection with BC-3 antibody, glycosaminoglycan chains
were removed from aggrecan fragments by digesting the mem-
branes with 0.01 units/ml chondroitin ABC lyase in 0.1 M
Tris/acetate, pH 8.0/1 % w/v BSA for 1 h at room temperature,
followed by digestion with keratanase (0.01 units/ml) and
keratanase II (0.002 units/ml) in 50 mM sodium acetate, pH-
6.5/1 % w/v BSA.
RESULTS AND DISCUSSION
Previous experiments digesting GI-G2 with low concentrations
(< 40 jug/ml) of MMPs had identified a major cleavage site
EN341-FFG where all MMPs showed activity. When MMP-8
was incubated with G1-G2 at high concentration (160 jug/ml) a
different pattern of fragments emerged (Figures 1 and 2). A
major product containing the G2 domain formed a broad band
on SDS/PAGE at 100-120 kDa (Figure 2A, a, lane 1) which
resolved into two components after keratanase treatment (Figure
2A, a, lane 2). The first band at 85-90 kDa was immunoreactive
with an anti G2 antiserum (Figure 2A, c) and contained the N-
terminal sequence FFGVG corresponding to the major MMP
cleavage site. The second band at 75-80 kDa was also G2
positive on immunoblotting and contained the N-terminal se-
quence ARGSV1 corresponding to the aggrecanase site. This
fragment also reacted strongly with a monoclonal antibody BC-
3 (Figure 2A, b, lane 2) which specifically recognises a peptide
with the ARGSVI N-terminal sequence [25]. Non-keratanase
treated digests were not immunolocalised with BC-3 antibody
(Fig. 2A, b, lane 1) indicating that the epitope was masked by
keratan sulphate chains. A third band (41-46 kDa) was identified
as a small G2-containing fragment with N-terminal sequence
LWQV corresponding to the second, minor MMP site. There
was also a small amount of undigested GI-G2 and a single Gl-
containing fragment with 50-56 kDa.
The ARGSVI-G2 fragment was produced exclusively by
MMP-8 and was not found in G1-G2 samples digested with
human recombinant fibroblast collagenase (< 390 jug/ml) (Fig-
ure 2C, lanes 4 and 5), stromelysin (rabbit bone, < 40 jug/ml;
human recombinant, < 100 jug/ml) (Figure 2D) or human gela-
tinase A (< 25 ug/ml) (results not shown) and these are all





















-68* . ........, jX...43




D .... ; - 200
-200











Figure 2 Degradation of aggrecan G1-G2 by MMPs and identification of an aggrecanase-type product following digestion with MMP-8
A, Digestion of G1-G2 (4 mg/ml) with HgCI2-activated human MMP-8 (160 ,ug/ml), SDS/PAGE and analysis by silver stain (a) or immunodetection with BC-3 (b) before (lane 1) and after (lane
2) keratanase treatment, (c) immunodetection with polyclonal anti-G2 antiserum. The N-terminal sequences of the G2 bands are shown. The short arrows mark undigested G1-G2 and the Gl domain
bands. B, Digestion of G1-G2 (4.2 mg/ml) with a purified, recombinant catalytic-domain fragment of human MMP-8 (192 ,ug/ml) and analysis by silver stain (a) or BC-3 immunoblot (b). C, Digestion
of G1-G2 (1 mg/ml) with MMP-8 (140 jug/ml) (lanes 2 and 3) or MMP-1 (140 ,ug/ml) (lanes 4 and 5), following activation of the enzymes by HgCl2 (lanes 2 and 4) or stromelysin and trypsin
(lanes 3 and 5); lane 1 is undigested. Analysis by silver stain (a) or BC-3 immunoblot (b). D, Digestion of G1-G2 (0.25 mg/ml) with purified rabbit-bone stromelysin (25 ,ug/ml), following activation
of the proenzyme with either plasmin (lane 1) or trypsin (lane 2), with analysis by silver stain. The N-terminal sequence of the G2 product derived from a trypsin-activated stromelysin digest is
shown.
GI-G2 substrate. The MMP-2 digests following keratanase
treatment produced a single 85 kDa G2 product. The MMP-3
digests (25-40 ,ug/ml) (Figure 2D) produced two bands (75 kDa
and 85 kDa) that appeared similar to those produced by
MMP-8. However, N-terminal sequence analysis of the 75 kDa
MMP-3-derived band revealed an N-terminal VILTVKP se-
quence (Figure 2D), and the band was not immunodetected with
BC-3 antibody irrespective of whether the prostromelysin was
activated with p-aminophenylmercuric acetate, plasmin or tryp-
sin. These results show that stromelysin, gelatinase and fibroblast
collagenase failed to cleave at the aggrecanase site.
MMP-8 was able to generate the ARGSVI-fragment following
activation with either HgCl2, or trypsin and stomelysin (Figure
2C, lanes 2 and 3). A recombinant catalytic domain or human
MMP-8 [14] was also able to produce the 75 kDa ARGSVI-
fragment (Figure 2B). Proteinase inhibitor experiments provided
further evidence that the cleavage was not due to a contaminating
proteinase of another class. The specific MMP inhibitor TIMP-
1, and the metal chelators EDTA and 1,10-phenanthroline each
blocked MMP-8 activity and no GI or G2 products were
formed. When the ratio of TIMP- :MMP-8 was less than 1: 1,
the activity of the enzyme was partially blocked, resulting in the
production of the 85 kDa band, but not the 75 kDa band (results
not shown). In contrast, 2 mM PMSF, 1 1tM pepstatin, 10 mM
n-ethylmaleimide,g/ml cystatin and 20 ,ug/ml E-64 were unable
to inhibit its action and in each case the 75 kDa ARGSVI-band
was detected by silver stain and immunoreactivity with BC-3.
Together with evidence from the recombinant enzyme these
results provide strong proof that MMP-8 was responsible for this
activity.
Although the aggrecanase activity of MMP-8 was detected
only at high enzyme concentration (160 jug/ml), this activity
could also be detected at concentrations as low as 10 ,ug/ml if
polyethylene glycol (PEG) 4000 was included in the digests.
Aggrecan is an expanded macromolecule with a large hydro-
dynamic domain which excludes other macromolecules (such as
enzymes) and concentrates them in a smaller excluded volume.
The addition of PEG 4000 in vivo thus mimics the effect of
aggrecan in cartilage in vivo. The results show that at 10lg/ml,
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Figure 3 Volume exclusion effect of polyethylene glycol 4000
G1-G2 (0.5 mg/ml) was digested overnight at 37 OC with HgCI2-activated MMP-8 (10 /,tg/
ml) either alone (lane 1) or in the presence of PEG 4000 at a final concentration of 2%,
5%, 10%, 15% or 20% (lanes 2-6 respectively). Aliquots were electrophoresed in duplicate on
5% SDS gels and analysed by silver stain (a) or BC-3 blot (b).
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75 kDa ARGSVI-fragments (Figure 3a and b, lane 1), however
when PEG 4000 was included in the digests at final concentrations
of 10% or greater, ARGSVI-fragments were readily detected by
silver stain (Figure 3a) and immunodetection with BC-3 (Figure
3b). These results show that polymers such as PEG can increase
the local concentration of enzyme by excluded-volume effects
and thereby affect their activity. Thus, the effective concentration
of proteinase in cartilage matrix may be high because of the
volume-exclusion effects of aggrecan, even though the total issue
concentration of enzyme might be quite low.
The 75 kDa ARGSVI-fragment was not present in digests that
did not also contain the 85 kDa FFGVG-fragment. Furthermore
the GI fragment released was always of similar size (- 50 kDa)
to that released by stromelysin and therefore did not contain the
32 amino acid F342-E373 sequence (Figure le). This suggested
that under the conditions tested, cleavage at the major MMP site
preceded cleavage at the E373-ARGSVI site. This was investigated
further in a time-course experiment, digesting GI-G2 with MMP-
8 (results not shown). At early times (4 h) the major fragment
was the 85 kDa G2 product, however with longer digestion times
(10 h and 21 h) the 75 kDa fragment was gradually produced at
the expense of the 85 kDa fragment, suggesting that the enzyme
cleaves initially at the MMP site and subsequently processes the
85 kDa FFGVG fragment to the 75 kDa ARGSVI fragment.
Other experiments showed that the G2 fragment with N-terminal
FFGVG (released by MMP-3 digestion of GI-G2) was a
substrate for further cleavage by MMP-8 at the aggrecanase site.
Further evidence that MMP-8 cleaves preferentially at the
major MMP site was provided by experiments in which two
synthetic 7-near peptides, IPENFFG and TEGEARG, substrate
analogues for each catabolic site, were tested as competitive
substrates. At a high molar excess (3000-fold) the IPENFFG
peptide reduced the amount ofARGSVI-fragment produced and
increased the amount of FFGVG-fragment present in digests of
GI-G2 (Figure 4a). This result suggests that the IPENFFG
peptide is a poor competitor for MMP-8 cleavage at the MMP
site, but a better competitor of enzyme action at the aggrecanase
site. This indicates that MMP-8 favours cleavage at the MMP
site because the peptide is able to compete for cleavage at
Figure 4 Effect of synthetic peptides IPENFFG and TEGEARG on MMP-8
action in vitro and on release of aggrecan fragments from cartilage explant
cultures
(a) G1-G2 (0.25 mg/ml) was digested with HgCI2-activated MMP-8 (100 ,ug/ml) for 16 h at
37 OC in the presence (lanes 3-8) or absence (lane 2) of either the IPENFFG peptide (lanes
3 and 4), the TEGEARG peptide (lanes 5 and 6) or both peptides together (lanes 7 and 8). The
peptides were present in 300-fold or 3000-fold molar excess over G1-G2. (b) Aliquots of
dialysed medium from cartilage explant cultures incubated with (lanes 3 and 4) or without (lanes
1 and 2) interleukin lca, and with (lanes 2 and 4) or without (lanes 1 and 3) the IPENFFG
peptides were electrophoresed on composite gels and analysed by Toluidine Blue staining or
BC-3 immunodetection.
E373-ARG, but it is not able to compete for cleavage at
N341-FFG. This is similar to the results obtained with low levels
of TIMP which also preferentially blocked cleavage at the
aggrecanase site. The TEGEARG peptide had no effect on
MMP-8 action on G1-G2, suggesting it is a weaker competitor
than IPENFFG.
The results show that in vitro MMP-8 cleaves primarily at
N341-FFGVG and that cleavage at the aggrecanase site occurs as
a secondary event. To investigate whether a similar pattern of
enzyme action occurred in tissue, cartilage explants were cultured
in the presence and absence of the IPENFFG peptide and IL-lIa.
The released aggrecan fragments were analysed for BC-3 epitope
(Figure 4b). Over a 24 h culture-period the IPENFFG peptide
was found to inhibit appearance of the ARGSVI epitope in
aggrecan products released from cartilage cultured with and
without IL-1. This is the same effect that was observed in vitro
with MMP-8, and suggests that in cartilage the IPENFFG
peptide is able to competitively inhibit an enzyme, presumably an
MMP, for cleavage at the aggrecanase site.
The identification of aggrecanase-derived fragments in human
synovial fluids initially suggested that aggrecanase was the
enzyme responsible in vivo for loss of aggrecan from cartilage.
However other data show that MMPs are also directly involved
in aggrecan degradation in vivo since GI fragments with C-
terminal sequences corresponding to MMP cleavage have been
extracted from [26] and immunolocalized in [27] human articular
cartilage. These findings suggest that bothMMP and aggrecanase
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activities are involved in aggrecan degradation in vivo, and
readily explain the occurrence of C-terminal DIPEN fragments
in cartilage matrix and N-terminal ARGSV fragments in joint
fluids. Other studies have also shown that MMPs have an
important role in aggrecan degradation as hydroxamic acid-
containing MMP inhibitors effectively reduce aggrecan release in
IL-1 and retinoate-stimulated matrix degradation [28-30].
Whether MMP-8 is the enzyme in cartilage that is responsible
for aggrecanase activity is unresolved, however there are no
reports of MMP-8 protein or antigen in cartilage, and we have
been unable to demonstrate MMP-8 mRNA in IL-1-stimulated
and control chondrocytes using reverse transcription-PCR
(J. Dudhia and T. E. Hardingham, personal communication).
Some results suggest that aggrecanase is not an MMP, for
although most aggrecan fragments isolated from synovial fluids
or explant medium have N-terminal ARGSVI sequences, the
purified MMPs (with the exception of MMP-8) appear unable to
cleave at this site in vitro. If, however, aggrecanase is one of the
members of the MMP family found in cartilage why has its
action not been identified in vitro? Possible reasons are (1) that
pure MMPs isolated from cartilage have not been tested; it is
possible that their substrate specificities differ from bone, fibro-
blast or other cell sources, (2) that conditions in cartilage matrix
such as enzyme: substrate ratio and concentration, pH and ionic
environment, and routes of activation may influence the rates of
attack at different substrate sites. Our data with PEG 4000
confirm that physical environment is an important aspect in
determining enzyme action. Until these questions are resolved it
would be premature to conclude that aggrecanase is not an
MMP.
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